DEFI Gestion

NanoPowers S.A. is a medical device company, founded in June 2004 that applies their unique and proprietary artificial muscle technology to restore or improve muscle function in humans.

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.